Inhaled insulin: current steps towards diabetes treatment
by Priya Patel; Bhavisha Kacha
International Journal of Nano and Biomaterials (IJNBM), Vol. 10, No. 3, 2024

Abstract: Diabetes mellitus is among the most serious health challenges worldwide. Diabetes is a chronic condition that develops when the pancreas fails to adequately make or utilise insulin. 537 million individuals worldwide have diabetes, and in 2021, 6.7 million people will die from the diabetes. There are 90 million adult diabetics in India, and the disease claims 747 thousand lives per year. The act of taking in air and occasionally other substances into your lungs is known as inhalation. Common types of inhalers include nebulisers, dry powder inhalers, soft mist inhalers, and meter-dose inhalers. The body responds quickly and easily to inhalation therapy. The bloodstream is affected directly by the lung, and given its accessibility and extensive alveolar-capillary network for drug absorption, inhalational insulin is a desirable alternative to systemic administration of the hormone. The Food and Drug Administration (FDA) officially approved the inhaled insulin Afrezza. In comparison to other unsuccessful inhaled insulin forms, this new, faster-acting inhalable insulin has a different and safer pharmacokinetic profile.

Online publication date: Tue, 02-Apr-2024

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Nano and Biomaterials (IJNBM):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com